Inventiva S.A. (IVA)
NASDAQ: IVA · Real-Time Price · USD
4.610
+0.060 (1.32%)
At close: Oct 13, 2025, 4:00 PM EDT
4.600
-0.010 (-0.22%)
After-hours: Oct 13, 2025, 4:27 PM EDT
Inventiva Revenue
Inventiva had revenue of 5.61M EUR in the half year ending June 30, 2025, a decrease of -15.28%. This brings the company's revenue in the last twelve months to 16.97M, down -10.36% year-over-year. In the year 2024, Inventiva had annual revenue of 14.09M, down -38.24%.
Revenue (ttm)
16.97M EUR
Revenue Growth
-10.36%
P/S Ratio
30.54
Revenue / Employee
143,814 EUR
Employees
118
Market Cap
608.58M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 14.09M | -8.73M | -38.24% |
Dec 31, 2023 | 22.82M | 4.77M | 26.41% |
Dec 31, 2022 | 18.05M | 9.55M | 112.35% |
Dec 31, 2021 | 8.50M | 3.24M | 61.52% |
Dec 31, 2020 | 5.26M | -6.03M | -53.39% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
IVA News
- 4 days ago - Inventiva S.A. (IVA) Analyst/Investor Day Transcript - Seeking Alpha
- 6 days ago - Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025 - GlobeNewsWire
- 12 days ago - Inventiva Appoints Andrew Obenshain as Chief Executive Officer - GlobeNewsWire
- 14 days ago - Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
- 14 days ago - Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update - GlobeNewsWire
- 14 days ago - Top Wall Street Forecasters Revamp Inventiva Expectations Ahead Of H1 Earnings - Benzinga
- 19 days ago - Inventiva to Host Analyst and Investor Event on October 8, 2025 - GlobeNewsWire
- 5 weeks ago - Inventiva to Participate in Upcoming September Investor Conferences - GlobeNewsWire